Pharma Stock Jumps 7% After Strong December Quarter Results; Check Q3 Performance

Synopsis: Bajaj Healthcare Limited reports 31.30% YoY revenue growth and a 41.04% QoQ net profit surge in Q3 FY26 results.

This Small-cap Pharma stock, engaged in manufacturing active pharmaceutical ingredients, intermediates, finished dosage forms, and nutraceuticals for the pharmaceutical and food industries globally, jumped 7.38 percent after the company reported strong December quarterly results.

​With a market capitalization of Rs. 1,241.85 crores, the share of Bajaj Healthcare Limited has reached an intraday high of Rs. 419.55 per equity share, rising nearly 7.38 percent from its previous day’s close price of Rs. 390.70. Since then, the stock has retreated and is currently trading at Rs. 393.20 per equity share.

Q3 FY26 Result

Coming into the quarterly results of Bajaj Healthcare Limited, the company’s consolidated revenue from operations increased by 31.30 percent YOY, from Rs. 122.79 crore in Q3 FY25 to Rs. 161.22 crore in Q3 FY26, and grew by 9 percent QoQ from Rs. 147.91 crore in Q2 FY26.

In Q3 FY26, Bajaj Healthcare Limited’s consolidated net profit increased by 33.70 percent YOY, reaching Rs. 15.67 crore compared to Rs. 11.72 crore during the same period last year. As compared to Q2 FY26, the net profit has increased by 41.04 percent, from Rs. 11.11 crore. The basic earnings per share increased by 9.44 percent and stood at Rs. 5.10 as against Rs. 4.66 recorded in the same quarter in the previous year, FY2025. Bajaj Healthcare Limited’s revenue and net profit have grown at a CAGR of 5.78 percent and 9.86 percent, respectively, over the last five years.

In terms of return ratios, the company’s ROCE and ROE stand at 11.4 percent and 10.7 percent, respectively. Bajaj Healthcare Limited has an earnings per share (EPS) of Rs. 15.8, and its debt-to-equity ratio is 0.45x.

Production Capacity

Bajaj Healthcare Limited has a strong manufacturing setup with an Active Pharmaceutical Ingredients (APIs) capacity of 730 metric tonnes per month. The company also operates intermediate production capacity of 94 metric tonnes per month and finished dosage formulation capacity of 100 million pieces per month.

Manufacturing Facilities & Global Presence

Bajaj Healthcare Limited operates a wide manufacturing network with 18 plants dedicated to active pharmaceutical ingredients and intermediates located across Maharashtra and Gujarat, including Tarapur, Vadodara, and Panoli. In addition, the company has two finished dosage formulation plants situated at Manjusar in Gujarat and Sinnar in Nashik, ensuring efficient and scalable production capabilities.

The company has a strong global presence, with its products exported to over 60 countries. Major export markets include Europe, the USA, Australia, Africa, the Middle East, South America, and several Asian countries such as Sri Lanka, South East Asia, Russia, and Korea, reflecting its wide international reach.

Business Development

Bajaj Healthcare Limited operates around 20 modern manufacturing facilities and employs more than 1,500 skilled professionals. It has approvals for 100 finished dosage formulations and serves a strong client base of over 575 customers across more than 60 countries. 

The company has filed over 60 DMFs, highlighting its regulatory strength. With a low debt-to-equity ratio of 0.45, Bajaj Healthcare remains financially stable while continuing to expand its global footprint and support government healthcare initiatives.

Bajaj Healthcare Limited is a well-established pharmaceutical company with over three decades of experience in manufacturing APIs, intermediates, and formulations. The company is one of the world’s major manufacturers of chlorhexidine base and a leading producer of ascorbic acid in India.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma Stock Jumps 7% After Strong December Quarter Results; Check Q3 Performance appeared first on Trade Brains.